PPARGC1A and Cognitive impairment: Taken together, these findings support the notion that abnormal mitochondrial dynamics plays a causal role in mitochondrial dysfunction and AD-related pathological and cognitive impairments and demonstrate PGC-1α as a potential therapeutic target for future drug development for AD.